GLMD
Galmed Pharmaceuticals Ltd
NASDAQ: GLMD · HEALTHCARE · BIOTECHNOLOGY
$0.56
-4.92% today
Updated 2026-04-29
Market cap
$4.12M
P/E ratio
—
P/S ratio
61.38x
EPS (TTM)
$-2.39
Dividend yield
—
52W range
$0 – $2
Volume
3.7M
Galmed Pharmaceuticals Ltd (GLMD) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | $762000.00 | $166000.00 | $32.92M | $24.26M | $16.45M | $19.64M | $90.60M | $77.14M | $52.38M | $36.60M | $16.56M | $16.63M | $18.50M |
| Cash & equivalents | — | $718000.00 | $137000.00 | $23.74M | $4.16M | $3.10M | $13.02M | $24.16M | $15.93M | $6.95M | $2.88M | $2.02M | $2.86M | $4.65M |
| Current assets | — | $732000.00 | $153000.00 | $32.15M | $23.38M | $15.73M | $19.15M | $90.41M | $76.43M | $51.81M | $36.05M | $14.72M | $13.24M | $16.12M |
| Total liabilities | — | $2.74M | $2.12M | $1.52M | $2.72M | $5.38M | $3.85M | $2.71M | $7.29M | $8.23M | $6.11M | $3.14M | $2.75M | $2.17M |
| Current liabilities | — | $513000.00 | $1.69M | $1.12M | $2.54M | $4.58M | $3.85M | $2.71M | $6.93M | $8.01M | $5.88M | $3.09M | $2.75M | $2.17M |
| Long-term debt | — | $1.82M | — | — | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | — | $-1.98M | $-1.95M | $31.41M | $21.55M | $11.07M | $15.79M | $87.89M | $69.85M | $44.15M | $30.50M | $13.42M | $13.88M | $16.33M |
| Retained earnings | — | $-10.16M | $-27.64M | $-36.74M | $-47.37M | $-64.32M | $-76.62M | $-86.47M | $-106.94M | $-135.71M | $-168.17M | $-186.04M | $-192.95M | $-200.47M |
| Accounts receivable | — | $10000.00 | $11000.00 | $64000.00 | $109000.00 | $284000.00 | $155000.00 | $51000.00 | $226000.00 | $66000.00 | $79000.00 | $124000.00 | $165000.00 | $209000.00 |
| Inventory | — | — | — | $-5.90M | $-270000.00 | $-254000.00 | $-100000.00 | — | $-27.94M | $-3.81M | $-932000.00 | $114000.00 | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — | — |